About

Dr. Jaroslaw Jedrych is an assistant professor of dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include dermatopathology and anatomic pathology. Dr. Jedrych received his M.D. from the Warsaw Medical University. He completed his residency in anatomic pathology at Yale School of Medicine, where he served as chief resident. He then completed his fellowship in oncologic pathology at Memorial Sloan Kettering Cancer Center, where he served as chief fellow, and a dermatopathology fellowship at University of Pittsburgh Medical Center.

Research topics

• Medicine
• Immunology
• Dermatology
• Genetics
• Oncology
• Internal medicine
• Biology
• Pathology

Selected publications

• Cyclin D1 demonstrates superior sensitivity and consistent nuclear expression compared with MiTF in cellular neurothekeoma

  Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2026-02-24

  articleSenior author
  PublisherDOI

• Anti-nuclear matrix protein 2 antibody-positive dermatomyositis associated with smouldering myeloma mimicking anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: A case of digital gangrene, palmar papules, and scrotal rash

  Modern Rheumatology Case Reports · 2025-01-01 · 1 citations

  article

  Dermatomyositis (DM) is an idiopathic inflammatory myopathy with characteristic cutaneous manifestations and systemic complications, including malignancy and interstitial lung disease (ILD). Myositis-specific autoantibodies (MSAs) define distinct disease subtypes, but significant clinical heterogeneity can still occur. Here, we report a unique case of smouldering myeloma-associated anti-nuclear matrix protein 2 (anti-NXP2) antibody-positive DM mimicking clinical features of anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody-positive DM, including digital ischemia and palmar papules (i.e. inverse Gottron's papules), and severe synovitis without clinically evident myopathy. Additionally, the patient exhibited a rare scrotal rash. This case expands the known spectrum of cutaneous and systemic manifestations in anti-NXP2 antibody-positive DM and emphasises the heterogeneous nature of DM, where significant clinical mimicry can occur despite the presence of a well-defined MSA. It highlights the need for further research into the immune mechanisms and biomarker profiles driving these mimicking DM phenotypes, which could improve early diagnosis, risk stratification, and targeted therapeutic strategies.

  PublisherDOI

• The Overlapping Clinicopathological Presentations of Pityriasis Lichenoides and Mycosis Fungoides

  Journal of Cutaneous Pathology · 2025-09-15 · 2 citations

  reviewOpen access

  Pityriasis lichenoides (PL) has traditionally been considered a benign cutaneous disorder with a diverse clinical presentation. This comprehensive literature review challenges that notion by exploring its histopathologic, immunopathologic, and molecular overlap with mycosis fungoides (MF). Through examination of lymphocyte populations, T-lymphocyte clonality, and aberrant immunohistochemical phenotypes, our findings indicate that a subset of PL cases, particularly those exhibiting a loss of pan-T-cell markers (CD2, CD5, CD7), or T-cell clonality, may have a closer association with MF. These findings highlight the need for heightened clinical awareness and surveillance in select PL cases, as early identification of MF may improve patient outcomes.

  PublisherOA PDFDOI

• A Trichoadenoma/Trichoepithelioma/Trichoblastoma-like Lesion in the Uterine Cervix Focally Mimics an Adenoid Basal Tumor

  International Journal of Gynecological Pathology · 2025-02-17 · 1 citations

  articleOpen access

  The presence of ectodermal adnexal structures in the uterine cervix, including sebaceous glands, hair follicles, and sweat glands, has been well documented in the literature. In theory, there exists the possibility of developing cutaneous-type lesions from the ectopic ectodermal structures in this location. Here we report the first case of cervical hair follicle-derived proliferations reminiscent of trichoadenoma, trichoepithelioma, and trichoblastoma (TA/TE/TB) in a 52-year-old woman who underwent a prophylactic hysterectomy due to a germline microphthalmia-associated transcription factor ( MITF ) gene mutation. The lesion was an incidental finding in the cervix, exhibiting a spectrum of morphologic features ranging from germinative TB with basaloid cells, to TE with some degree of infundibulocystic differentiation, to well-differentiated TA. In some areas, hair follicle-like structures were associated with sebaceous glands, forming pilosebaceous units. The proliferations in the TB-like area resembled adenoid basal epithelioma/carcinoma; however, ancillary studies, particularly patchy p16 expression and non-detection of HPV, argued against this diagnosis. Similar to adenoid basal tumors, the TB-like lesion focally expressed NKX3.1, suggesting that it might be related to ectopic prostatic tissue or exhibit prostatic-lineage differentiation. While the theory of misplaced embryonal tissue, or an acquired metaplastic process, has been discussed, the histopathologic origin of these lesions remains largely unknown.

  PublisherOA PDFDOI

• LB1027 Spatial transcriptomic profiling reveals fibroblast activation and inflammatory signatures in calcinosis cutis of autoimmune connective tissue diseases

  Journal of Investigative Dermatology · 2025-07-21

  articleOpen access
  PublisherOA PDFDOI

• Assessment of Cutaneous and Mucosal Direct Immunofluorescence Testing Practices in the US

  JAMA Dermatology · 2025-04-04 · 4 citations

  article

  Importance: Direct immunofluorescence (DIF) testing has been an important ancillary tool for the diagnosis of various inflammatory mucocutaneous conditions for more than 50 years. Current DIF test panels are based on historical clinical descriptions; few studies have rigorously addressed preanalytical, analytical, and/or postanalytical aspects, and even fewer have been replicated or validated. Recent unresolved key issues include whether DIF testing and test panels should be triaged or truncated based on clinical indication or histopathologic findings. Objective: To assess levels of consensus regarding practical aspects of DIF testing among immunodermatology testing specialists in the US. Design, Setting, and Participants: Using modified Delphi methods with a priori characterized criteria, a survey containing 54 statements pertaining to DIF testing was created and distributed to assess consensus. Statements not initially reaching consensus were discussed in 2 live virtual sessions, which were supplemented by relevant literature review and free-text survey comments. These statements were then reassessed in a second survey. Immunodermatology testing specialists in US academic institution-based and independent laboratories were invited based on serving as immunodermatology laboratory medical directors, authoring pertinent literature, or delivering relevant talks at major conferences or by referral. The first survey was conducted from January to February 2024, and the second survey was conducted from March to April 2024. Main Outcomes and Measures: The primary measured outcome was degree of consensus for various DIF testing practice, including DIF testing triage by histopathology/dermatopathology findings and DIF testing panel tailored truncations by clinical indication. Results: A total of 23 respondents to the survey invitation had a mean (SD) of 18.5 (11.1) years and median (range) of 20.0 (1.5-46.0) years in immunodermatology laboratory practice. Consensus was achieved for 46 of 54 statements (85.2%) in the initial survey and for an additional 4 statements in the second survey (50 of 54 [92.6%]). Strong consensus was found against tailored truncation of DIF panel based on the clinical indication in the first survey round. The general acceptability of triaging specimens for DIF testing based on histopathology findings remained without consensus after both surveys. Conclusions and Relevance: Overall, participating US specialists in immunodermatology laboratory testing agreed on many practical aspects of DIF testing, including matters not queried previously. The findings also revealed areas of continued controversy and identified issues for prioritized future study.

  PublisherDOI

• Abstract CT097: Associations between percent residual viable tumor (%RVT) and efficacy with perioperative nivolumab (NIVO) for resectable NSCLC in CheckMate 77T

  Cancer Research · 2025-04-25 · 4 citations

  article

  Abstract Background: In CheckMate 816, lower %RVT in primary tumor (PT) and lymph node (LN) after neoadjuvant (neoadj) NIVO + chemo correlated with improved EFS in patients (pts) with resectable NSCLC. To further evaluate %RVT as a surrogate for EFS, we report an exploratory analysis of efficacy with adjuvant (adj) NIVO after neoadj treatment (tx) by LN involvement, nodal (N) status, and %RVT in PT and LN in CheckMate 77T. Methods: Pts with resectable stage IIA-IIIB NSCLC were randomized to neoadj NIVO + chemo Q3W (up to 4 cycles [cyc]) followed by adj NIVO Q4W (up to 13 cyc) or neoadj placebo (PBO) + chemo Q3W (up to 4 cyc) followed by adj PBO Q4W (up to 13 cyc). Primary endpoint: EFS per BICR. This analysis, which included pts with pathologically evaluable samples who had definitive surgery and ≥ 1 adj tx dose, assessed EFS by LN involvement, N status, %RVT in PT and LN, and associations between %RVT and EFS per time-dependent ROC curve analysis. Results: BL characteristics were similar between tx arms (NIVO, 123; PBO, 134; median f/u, 33.3 mo). NIVO improved EFS v PBO regardless of LN involvement or N status (Table). A higher proportion of pts treated with NIVO had 0% RVT in PT and/or LN v PBO (52% v 20%). In pts with LN involvement, 2-y EFS rates with NIVO were higher in pts with 0% RVT in both PT and LN (90%) or 0% RVT in PT or LN (85%) v > 0% RVT in both PT and LN (76%). Area under the ROC curve for %RVT-PT in pts with PT-only disease was 0.83. 2-y EFS rates with NIVO were 94%, 77%, and 50% in pts with 0-5%, > 5-80%, and > 80% RVT-PT, respectively; similar results were seen in all pts with pathologically evaluable samples whether they received adj tx or not. Conclusions: In this exploratory analysis, NIVO improved EFS v PBO, particularly in pts with LN involvement and regardless of N status. %RVT also associated with EFS in a continuous manner, supporting %RVT as a surrogate for EFS and highlighting its prognostic value in pts who receive perioperative NIVO. Citation Format: Julie Stein Deutsch, Ashley Cimino-Mathews, Elizabeth Thompson, Edward Gabrielson, Peter Illei, Jaroslaw Jedrych, Ezra Baraban, Alex S. Baras, Mariano Provencio Pulla, Tina Cascone, Jonathan D. Spicer, Mark M. Awad, Fumihiro Tanaka, Jie He, Shun Lu, Cinthya Coronado Erdmann, Vipul Devas, Sumeena Bhatia, Janis M. Taube. Associations between percent residual viable tumor (%RVT) and efficacy with perioperative nivolumab (NIVO) for resectable NSCLC in CheckMate 77T [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT097.

  PublisherDOI

• Pan-tumor harmonization of pathologic response assessment for standardized data collection in neoadjuvant IO trials (PATHdata): Final analysis of a multi-institutional reproducibility study.

  Journal of Clinical Oncology · 2024-06-01 · 1 citations

  article

  2515 Background: Immunotherapeutic agents are now being investigated for treating earlier-stage cancers. Radiographic assessment by RECIST, widely used to assess treatment response in clinical trials for advanced cancers, has limitations in the neoadjuvant setting; and pathologic response assessment is increasingly being used as a primary and/or secondary endpoint. To that end, a pan-tumor scoring system for assessing pathologic response was developed (1,2). This scoring system allows for the quantitative assessment of residual viable tumor (RVT) in multiple locations: i.e. primary and lymph node (LN) or distant metastases, akin to RECIST. %RVT scored using this system been associated with patient outcomes after treatment with anti-PD-1-based therapies. Additionally, %RVT in LN has been shown to have additive value to %RVT in the primary tumor when predicting patient survival (3). As a result, pathologists are now being asked to score pathologic response in the primary tumor and LN as a part of ongoing clinical trials and routine clinical care. Here, we evaluated the reproducibility of %RVT scoring using pan-tumor immune-related pathologic response criteria (irPRC). Methods: A multi-institutional, international study led by the Society for Immunotherapy of Cancer was initiated to assess the concordance of pathologic response assessment in resection specimens from patients treated with anti-PD-1-based therapies. Online lecture-based modules for irPRC scoring were developed, and 14 pathologists from multiple institutions, including academic and industry partners, were trained to score H&E-stained slides. The pathologists have scored n=37 pathology cases from resection specimens and on-treatment biopsies from >10 different tumor types, in part derived from phase II/III clinical trials. %RVT in the primary tumor and LN from patient specimens were scored separately (total of n=374 slides scored by each pathologist). Results: At the first interim analysis, scoring of pathologic response using irPRC was shown to be highly reproducible, irrespective of disease location (i.e. primary tumor vs lymph node metastasis). The second half of the study is nearing completion, and these reproducibility numbers will be finalized and presented in the final abstract. Extended analyses will also be presented that include subset analyses by tumor type. Conclusions: The results will be interpreted and presented in the context of the larger field for pathologic response assessment. A post-study survey completed by the participating pathologists will be used to refine irPRC training materials prior to dissemination to the wider immuno-oncology community. 1. Cottrell et al. Ann Oncol2018. 2. Stein et al. Clin Can Res 2020. 3. Deutsch, et al. Nat Med 2023.

  PublisherDOI

• Concurrent autoimmune blistering diseases in VEXAS syndrome: a report of two cases

  Clinical and Experimental Dermatology · 2024-07-23 · 2 citations

  article

  VEXAS (vacuoles, E1-enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently characterized autoinflammatory condition driven by myeloid cell dysregulation. We report two patients with concurrent diagnoses of VEXAS syndrome and autoimmune blistering diseases – pemphigus vulgaris and dermatitis herpetiformis – highlighting a previously undescribed association between innate immune dysregulation and autoantibody-mediated skin diseases.

  PublisherDOI

• The dermatopathologist–patient consultation program: A pilot study on patient perspectives and interest

  Journal of Cutaneous Pathology · 2024-04-03

  articleOpen accessSenior author

  BACKGROUND: Despite the integral contribution of dermatopathologists in diagnosing skin lesions, their role often remains unclear to patients, likely due to little face-to-face interaction. More healthcare systems have begun introducing patient-pathologist consultation programs that allow patients to discuss results with a pathologist and view tissue under a microscope. To our knowledge, only one study has been published exploring patient perspectives of these programs and no studies exist regarding interest in dermatopathology. METHODS: An anonymous survey was distributed via online support groups for various dermatologic diagnoses. RESULTS: Patients demonstrated a high level of interest in the dermatopathologist-patient consultation program, with 81.3% expressing at least moderate interest in discussing their diagnosis with a dermatopathologist and 79.2% expressing at least moderate interest in examining their tissue under the microscope with a dermatopathologist. The rationale for interest included various themes: (1) knowledge/understanding, (2) empowerment, (3) emotional support, (4) general interest, and (5) improved trust. CONCLUSIONS: Patients with cancerous and non-cancerous dermatologic diagnoses demonstrate high interest in a dermatopathologist-patient consultation program. Efforts to pilot this type of program can build upon the infrastructure of current pathologist consultation programs. Future efforts should be taken by hospital leadership, clinicians, and dermatopathologists to determine physician interest and address logistical challenges to the implementation of these programs.

  PublisherOA PDFDOI

Frequent coauthors

• Joel C. Sunshine

  Johns Hopkins University

  31 shared

• Julie Stein Deutsch

  Johns Hopkins University

  25 shared

• Ashley Cimino‐Mathews

  24 shared

• Peter B. Illei

  23 shared

• Janis M. Taube

  Foundation Center

  23 shared

• Robert A. Anders

  Johns Hopkins University

  22 shared

• Daphne Wang

  Johns Hopkins University

  22 shared

• Ludmila Danilova

  21 shared

Education

• M.D.

  Warsaw Medical University

• Other, Oncologic Pathology

  Memorial Sloan Kettering Cancer Center

• Other, Dermatopathology

  University of Pittsburgh Medical Center

• Other, Anatomic Pathology

  Yale School of Medicine